C18orf12

Across TCGA pan-cancer cohorts, C18orf12 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated C18orf12 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher C18orf12 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated C18orf12 expression acts as an unfavorable survival marker, although some lineages such as SKCM and STAD show a favorable association.

LIHC, THYM, and PCPG are the cancer types where C18orf12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.051	0.783	<.001	108	view →
THYM	OS	Tertile	All	0.186	0.931	<.001	45	view →
PCPG	DFS	Tertile	All	0.127	0.893	<.001	45	view →
SKCM	DFS	Tertile	All	0.889	0.610	.007	33	view →
READ	DFS	Tertile	All	0.179	0.701	.022	27	view →
STAD	DFS	Tertile	III,IV	0.782	0.553	.015	18	view →
TGCT	DFS	Tertile	II,III,IV	0.088	0.917	.010	18	view →
HNSC	DFS	Tertile	All	0.820	0.686	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

C18orf12–LIHC (OS)

Open the LIHC breakdown →